These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12100900)

  • 1. Use of recombinase activation gene-2 deficient mice to ascertain the role of cellular and humoral immune responses in the development of chronic rejection.
    Sun H; Woodward JE; Subbotin VM; Kuddus R; Logar AJ; Schaefer AT; Aitouche A; Rao AS
    J Heart Lung Transplant; 2002 Jul; 21(7):738-50. PubMed ID: 12100900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marked mitigation of transplant vascular sclerosis in FasLgld (CD95L) mutant recipients. The role of alloantibodies in the development of chronic rejection.
    Subbotin V; Sun H; Aitouche A; Salam A; Valdivia LA; Fung JJ; Starzl TE; Rao AS
    Transplantation; 1999 May; 67(10):1295-300. PubMed ID: 10360580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intimal thickening develops without humoral immunity in a mouse aortic allograft model of chronic vascular rejection.
    Chow LH; Huh S; Jiang J; Zhong R; Pickering JG
    Circulation; 1996 Dec; 94(12):3079-82. PubMed ID: 8989111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abrogation of chronic rejection in a murine model of aortic allotransplantation by prior induction of donor-specific tolerance.
    Subbotin V; Sun H; Aitouche A; Valdivia LA; Fung JJ; Starzl TE; Rao AS
    Transplantation; 1997 Sep; 64(5):690-5. PubMed ID: 9311704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked inhibition of transplant vascular sclerosis by in vivo-mobilized donor dendritic cells and anti-CD154 mAb.
    Wang Z; Morelli AE; Hackstein H; Kaneko K; Thomson AW
    Transplantation; 2003 Aug; 76(3):562-71. PubMed ID: 12923445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and restoration of second-set liver allograft rejection in presensitized mice: the role of "passenger" leukocytes, donor major histocompatibility complex antigens, and host cytotoxic effector mechanisms.
    Fu F; Li W; Lu L; Thomson AW; Fung JJ; Qian S
    Transplantation; 1999 Feb; 67(3):444-50. PubMed ID: 10030293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of hyperacute rejection of skin allografts by CD8+ lymphocytes.
    Yoshimura R; Chargui J; Aitouche A; Veyron P; Touraine JL
    Transplantation; 2000 Apr; 69(7):1452-7. PubMed ID: 10798770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fas-mediated cytotoxicity is not required for rejection of murine nonvascularized heterotopic cardiac allografts.
    Djamali A; Odorico JS
    Transplantation; 1998 Dec; 66(12):1793-801. PubMed ID: 9884278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice.
    Wasowska BA; Qian Z; Cangello DL; Behrens E; Van Tran K; Layton J; Sanfilippo F; Baldwin WM
    Transplantation; 2001 Mar; 71(6):727-36. PubMed ID: 11330533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting.
    Wang H; Hosiawa KA; Min W; Yang J; Zhang X; Garcia B; Ichim TE; Zhou D; Lian D; Kelvin DJ; Zhong R
    J Immunol; 2003 Oct; 171(7):3823-36. PubMed ID: 14500684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of donor MHC class I or class II antigen deficiency on first- and second-set rejection of mouse heart or liver allografts.
    Qian S; Fu F; Li Y; Lu L; Rao AS; Starzl TE; Thomson AW; Fung JJ
    Immunology; 1996 May; 88(1):124-9. PubMed ID: 8707337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of alloantibodies on corneal allograft survival.
    Hegde S; Mellon JK; Hargrave SL; Niederkorn JY
    Invest Ophthalmol Vis Sci; 2002 Apr; 43(4):1012-8. PubMed ID: 11923241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporine immunosuppression does not prevent the production of donor-specific antibody capable of mediating allograft vasculopathy.
    Gareau AJ; Nashan B; Hirsch GM; Lee TD
    J Heart Lung Transplant; 2012 Aug; 31(8):874-80. PubMed ID: 22554675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance.
    Zhou P; Szot GL; Guo Z; Kim O; He G; Wang J; Grusby MJ; Newell KA; Thistlethwaite JR; Bluestone JA; Alegre ML
    J Immunol; 2000 Nov; 165(10):5580-7. PubMed ID: 11067913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Il-12 antagonism enhances apoptotic death of T cells within hepatic allografts from Flt3 ligand-treated donors and promotes graft acceptance.
    Li W; Lu L; Wang Z; Wang L; Fung JJ; Thomson AW; Qian S
    J Immunol; 2001 May; 166(9):5619-28. PubMed ID: 11313402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are corneal cells susceptible to antibody-mediated killing in corneal allograft rejection?
    Hargrave SL; Mayhew E; Hegde S; Niederkorn J
    Transpl Immunol; 2003; 11(1):79-89. PubMed ID: 12727479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innate immunity alone is not sufficient for chronic rejection but predisposes healed allografts to T cell-mediated pathology.
    Zecher D; Li Q; Williams AL; Walters JT; Baddoura FK; Chalasani G; Rothstein DM; Shlomchik WD; Demetris AJ; Lakkis FG
    Transpl Immunol; 2012 Mar; 26(2-3):113-8. PubMed ID: 22226941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cells play a critical role in cardiac allograft vasculopathy in an interleukin-6--dependent manner.
    Zhang ZX; Huang X; Jiang J; Lian D; Min WP; Liu W; Haig A; Jevnikar AM
    Transplantation; 2014 Nov; 98(10):1029-39. PubMed ID: 25286056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor T cell activation initiates small bowel allograft rejection through an IFN-gamma-inducible protein-10-dependent mechanism.
    Zhang Z; Kaptanoglu L; Haddad W; Ivancic D; Alnadjim Z; Hurst S; Tishler D; Luster AD; Barrett TA; Fryer J
    J Immunol; 2002 Apr; 168(7):3205-12. PubMed ID: 11907073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4+ T-cell-dependent immune damage of liver parenchymal cells is mediated by alloantibody.
    Horne PH; Lunsford KE; Eiring AM; Wang Y; Gao D; Bumgardner GL
    Transplantation; 2005 Aug; 80(4):514-21. PubMed ID: 16123727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.